ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Clinical trials for ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with tough leukemia: early trial tests drug to boost chemo
Disease control OngoingThis early-stage study is testing the safety and best dose of a new drug called uproleselan when given with two standard chemotherapy drugs (fludarabine and cytarabine). It is for children and teenagers (ages 1-17) whose acute myeloid leukemia, myelodysplastic syndrome, or mixed …
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 04, 2026 09:20 UTC
-
New combo therapy aims to wipe out lingering leukemia cells in older patients
Disease control OngoingThis study is for older adults newly diagnosed with a type of blood cancer called acute myeloid leukemia (AML) who cannot or choose not to have intensive chemotherapy. It compares two treatment plans: the current standard two-drug combination versus adding a third immunotherapy d…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Scientists test drug combo to fight tough blood cancer
Disease control OngoingThis study is testing if adding a drug called pomalidomide to standard chemotherapy works better for adults newly diagnosed with a specific, harder-to-treat type of acute myeloid leukemia (AML). About 50 participants will be randomly assigned to receive either the standard chemo …
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New pill trial targets genetic flaw in tough blood cancers
Disease control OngoingThis study is testing if a pill called olaparib can help control advanced blood cancers (acute myeloid leukemia or myelodysplastic syndrome) that have come back or haven't responded to standard treatments. It is for adults whose cancer has a specific genetic change called an IDH …
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope for AML patients: can a Cancer-Fighting drug boost Chemo's power?
Disease control OngoingThis study is testing if adding the immunotherapy drug pembrolizumab to standard chemotherapy works better for adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if the combination helps more patients achieve a deep remission with no detectable cancer ce…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Scientists test new drug cocktail in fight against tough blood cancer
Disease control OngoingThis early-stage study is testing a combination of three drugs—bortezomib, sorafenib, and decitabine—to treat acute myeloid leukemia (AML). The main goal is to find the safest and most effective dose. The study is for adults with AML who are older, have a type that is hard to tre…
Matched conditions: ACUTE MYELOID LEUKEMIA POST CYTOTOXIC THERAPY
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 02, 2026 15:24 UTC